Literature DB >> 16632085

Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable.

John T Farrar1, Robert H Dworkin, Mitchell B Max.   

Abstract

In randomized controlled trials, no single definition of response is ideal for all purposes. We propose a method to present in a simple fashion the likelihood of response over a full range of response levels, which will facilitate a better understanding of clinical trial data. We present the technique called the cumulative proportion of responders analysis (CPRA) and its application to four pain clinical trial data sets as examples. The CPRA can be used to present the proportion of responders over the entire range of possible cut-off points as a graph. This allows the reader to compare treatment groups at any responder level that is valid for their patient population. Whether as a primary or secondary approach to a clinical trial of pain therapy, the display of data in a CPRA format may be useful in the understanding of results and applicability to patient care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16632085     DOI: 10.1016/j.jpainsymman.2005.08.018

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  38 in total

1.  [Physicians do not treat averages--but therapy responders!].

Authors:  C Maier; R Baron
Journal:  Schmerz       Date:  2012-02       Impact factor: 1.107

Review 2.  Reporting of Design Features and Analysis Details in Randomized Clinical Trials of Procedural Treatments for Cancer Pain: An ACTTION Systematic Review.

Authors:  Daniel Rothstein; Rachel A Kitt; Shannon M Smith; Salahadin Abdi; Mitchell P Engle; Michael P McDermott; Srinivasa N Raja; Dennis C Turk; Robert H Dworkin; Jennifer S Gewandter
Journal:  Reg Anesth Pain Med       Date:  2017 May/Jun       Impact factor: 6.288

3.  Applying area-under-the-curve analysis to enhance interpretation of response profiles: an application to sleep quality scores in patients with fibromyalgia.

Authors:  Andrew G Bushmakin; Joseph C Cappelleri; Gergana Zlateva; Alesia Sadosky
Journal:  Qual Life Res       Date:  2010-10-27       Impact factor: 4.147

4.  The effect of OPC Factor on energy levels in healthy adults ages 45-65: a phase IIb randomized controlled trial.

Authors:  Patrick J LaRiccia; John T Farrar; Mary D Sammel; Joseph J Gallo
Journal:  J Altern Complement Med       Date:  2008-07       Impact factor: 2.579

5.  Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Authors:  Daniel E Falk; Raye Z Litten; Raymond F Anton; Henry R Kranzler; Bankole A Johnson
Journal:  J Stud Alcohol Drugs       Date:  2014-03       Impact factor: 2.582

6.  The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.

Authors:  Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch
Journal:  Pain Med       Date:  2010-01-15       Impact factor: 3.750

Review 7.  Responder analyses in randomised controlled trials for chronic low back pain: an overview of currently used methods.

Authors:  Nicholas Henschke; Annefloor van Enst; Robert Froud; Raymond W G Ostelo
Journal:  Eur Spine J       Date:  2014-01-14       Impact factor: 3.134

8.  Pragmatic Implementation of a Stratified Primary Care Model for Low Back Pain Management in Outpatient Physical Therapy Settings: Two-Phase, Sequential Preliminary Study.

Authors:  Jason M Beneciuk; Steven Z George
Journal:  Phys Ther       Date:  2015-04-09

Review 9.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

10.  Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.

Authors:  R A Moore; O A Moore; S Derry; P M Peloso; A R Gammaitoni; H Wang
Journal:  Ann Rheum Dis       Date:  2009-04-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.